We have extensive experience in design and execution of pre-clinical studies for drug development within oncology and immuno-oncology. We can perform studies with cell line based models as well as PDX models available through the START-MINERVA collaboration. Studies can be designed to take advantage of our capabilities of orthotopic and metastatic models, external radiation therapy, and advanced non-invasive imaging.

Our capabilities

Subcutaneous xenograft models (rats and mice)

Targeted radionuclide therapy

Orthotopic xenograft models

PET/CT imaging

Subcutaneous and orthotopic syngeneic models

SPECT/CT imaging

PDX models, including orthotopic implantation

MR imaging

External radiation therapy

Optical (bioluminescence) imaging

Contact Person

Carsten H. Nielsen, PhD

Co-founder, CEO